Novartis Czech Republic's operating cash flow stood at CZK -16.5 mil in 2017, down 126% when compared to the previous year. Historically, between 2000 - 2017, the firm’s operating cash flow reached a high of CZK 348 mil in 2007 and a low of CZK -339 mil in 2006.
Novartis Czech Republic's total investments stood at CZK -16.7 mil and accounted for 0.268% of sales in 2017. This is compared to an average of 0.695% as seen over the last five years.
Cash from financing amounted to CZK 0 mil, so the company generated CZK -33.2 mil net cash in 2017.
At the end of 2017, the company had a net debt of CZK 51.2 mil, or 0.371x of EBITDA and 7.85% of equity. Net working capital amounted to CZK 1,242 mil, or 19.7% of sales. Cash conversion cycle is negative and reached 79.3 days days in 2017. This means Novartis Czech Republic generates revenue from customers before it has to pay its suppliers for inventory, among other things.
You can see all the company’s data at Novartis Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
